RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity

BACKGROUND: Endocrine-resistant breast cancers have elevated expression of XBP1, where it drives endocrine resistance by controlling the expression of its target genes. Despite the in-depth understanding of the biological functions of XBP1 in ER-positive breast cancer, effectors of endocrine resista...

Descripción completa

Detalles Bibliográficos
Autores principales: Barua, David, Sultana, Afrin, Islam, Md Nahidul, Cox, Fergus, Gupta, Ananya, Gupta, Sanjeev
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061897/
https://www.ncbi.nlm.nih.gov/pubmed/36997866
http://dx.doi.org/10.1186/s12885-023-10745-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061897/
https://www.ncbi.nlm.nih.gov/pubmed/36997866
http://dx.doi.org/10.1186/s12885-023-10745-1

Ejemplares similares